Clinical trials
Phase 1 Prostatic Neoplasms trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Recruiting | 8 |
| Active, not recruiting | 4 |
| Unknown status | 3 |
| Terminated | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Janssen Research & Development, LLC | 5 |
| Aragon Pharmaceuticals, Inc. | 2 |
| Cambridge University Hospitals NHS Foundation Trust | 2 |
| Evgen Pharma | 2 |
| University of Oxford | 2 |
| Agenus Inc. | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Arvinas Androgen Receptor, Inc. | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 44 |
| Ovarian Neoplasms | 8 |
| Breast Neoplasms | 7 |
| Neoplasm Metastasis | 6 |
| Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Pancreatic Neoplasms | 4 |
| Urinary Bladder Neoplasms | 4 |
| Colorectal Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.